Reviewer's report

Title: Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports

Version: 1 Date: 6 February 2014

Reviewer: Dick Tibboel

Which of the following best describes what type of case report this is?: Findings that shed new light on the possible pathogenesis of a disease or an adverse effect

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: No

Does the case report have explanatory value?: No

Does the case report have diagnostic value?: Yes

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

Comments to authors:

These are 2 interesting cases of the conversion of Sildenafil to a sublingual application in 2 very complicated cases, one even with a diagnosis of ACD.

The case report is justified based on the transfer from enteral to sublingual but it is very difficult the identify the individual contribution of Sildenafil in the success of therapy as both patients received more than 15 different drugs for a variety of reasons. At least a significant difference of the C-average was determined in both patients.

Apart from the case description I feel it is important to make a note of the recent FDA-warning for the use of Sildenafil as published in the American Journal of Respiratory and Critical Care Medicine, 2013 and the comment from the working
group on PH in the USA.

**Quality of written English:** Acceptable

**Declaration of competing interests:**

I have no competing interests.